Results 271 to 280 of about 399,504 (355)

Clinical and Molecular Effect of the Anti–IL‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

open access: yesAllergy, EarlyView.
At Week 12, aletekitug was associated with a −68.3% percentage change from baseline in EASI score. Aletekitug improved the transcriptional profile of lesional skin towards that of non‐lesional skin at Week 4 and Week 12. Aletekitug was well‐tolerated; no serious adverse event or death occurred, and no patient withdrew due to an adverse event.
Joanne Ellis   +32 more
wiley   +1 more source

Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis

open access: yesHepatology, 2014
M. Granzow   +21 more
semanticscholar   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Histopathological Characterization and Differential Expression of miRNAs in Male Pediatric Patients With Lichen Sclerosus

open access: yesAndrology, EarlyView.
ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang   +10 more
wiley   +1 more source

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm [PDF]

open access: bronze, 2015
Anthony D. Pomicter   +7 more
openalex   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

open access: yesBritish Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan   +2 more
wiley   +1 more source

The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s Encephalopathy

open access: yesDrug Metabolism And Disposition, 2014
Qiang Zhang   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy